ProQR Therapeutics (NASDAQ:PRQR) Director Bart Filius Buys 150,000 Shares

ProQR Therapeutics N.V. (NASDAQ:PRQR) Director Bart Filius bought 150,000 shares of ProQR Therapeutics stock in a transaction on Friday, July 17th. The shares were acquired at an average price of $1.72 per share, for a total transaction of $258,000.00. Following the completion of the acquisition, the director owned 300,000 shares in the company, valued at $516,000. This represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Bart Filius also recently made the following trade(s):

• On Friday, June 26th, Bart Filius bought 150,000 shares of ProQR Therapeutics stock. The stock was purchased at an average cost of $1.54 per share, with a total value of $231,000.00.

ProQR Therapeutics Trading Down 0.3%

Shares of NASDAQ PRQR traded down $0.01 during midday trading on Tuesday, reaching $1.73. 229,868 shares of the company were exchanged, compared to its average volume of 713,946. The stock has a market cap of $181.75 million, a P/E ratio of -3.45 and a beta of 0.04. ProQR Therapeutics N.V. has a 1 year low of $1.33 and a 1 year high of $3.10. The stock has a fifty day simple moving average of $1.65 and a 200 day simple moving average of $1.65.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings data on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.15). The company had revenue of $2.35 million during the quarter, compared to analysts’ expectations of $5.19 million. ProQR Therapeutics had a negative return on equity of 84.87% and a negative net margin of 331.33%. As a group, analysts forecast that ProQR Therapeutics N.V. will post -0.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Weiss Ratings downgraded shares of ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. JonesTrading dropped their price target on shares of ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, June 26th. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a report on Wednesday, May 27th. Chardan Capital decreased their target price on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, June 26th. Finally, Wall Street Zen lowered shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, ProQR Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $7.33.

Hedge Funds Weigh In On ProQR Therapeutics

Hedge funds have recently modified their holdings of the stock. Osaic Holdings Inc. boosted its position in ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 4,500 shares during the last quarter. Guggenheim Capital LLC purchased a new stake in shares of ProQR Therapeutics during the 4th quarter worth about $35,000. Moody Lynn & Lieberson LLC acquired a new stake in shares of ProQR Therapeutics during the 4th quarter valued at about $50,000. Invesco Ltd. bought a new stake in shares of ProQR Therapeutics in the 4th quarter valued at approximately $51,000. Finally, Axiom Investment Management LLC bought a new stake in ProQR Therapeutics in the first quarter worth $53,000. 32.65% of the stock is owned by institutional investors and hedge funds.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.